Caligan Partners LP
An institutional investment manager in NEW YORK, NY. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1727492.
- Reported value$2.13bn
- Positions28
Holdings: 28 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Liquidia CorporationLQDA | COM NEW | 53635D202 | 647 | 30.5% | 8,118,892 | Unchanged | |
| Revolution Medicines IncRVMD | COM | 76155X100 | 367 | 17.3% | 1,961,795 | Added+308,987 | |
| Abivax SAABVX | SPONSORED ADS | 00370M103 | 208 | 9.8% | 1,557,924 | Added+96,000 | |
| Vaxcyte IncPCVX | COM | 92243G108 | 127 | 6.0% | 2,188,636 | Added+127,917 | |
| Exelixis IncEXEL | COM | 30161Q104 | 84.5 | 4.0% | 1,553,262 | Unchanged | |
| Tango Therapeutics IncTNGX | COM | 87583X109 | 78.2 | 3.7% | 2,500,103 | Added+91,305 | |
| Avalo Therapeutics IncAVTX | COM NEW | 05338F306 | 58.5 | 2.8% | 3,163,866 | Added+1,528,843 | |
| Xenon Pharmaceuticals IncXENE | COM | 98420N105 | 53.7 | 2.5% | 889,944 | Reduced−503,083 | |
| Adma Biologics IncADMA | COM | 000899104 | 47.9 | 2.3% | 5,725,007 | Added+968,496 | |
| Revolution Medicines IncRVMD | COM | 76155X100 | 47.2 | 2.2% | 251,800 | Call | Added+22,900 |
| LB Pharmaceuticals IncLBRX | COM SHS | 50180M108 | 46.7 | 2.2% | 1,438,070 | Unchanged | |
| Immunocore Holdings plcIMCR | ADS | 45258D105 | 43.9 | 2.1% | 1,381,317 | New+1,381,317 | |
| Viridian Therapeutics IncVRDN | COM | 92790C104 | 40.3 | 1.9% | 2,193,981 | New+2,193,981 | |
| VOR Biopharma IncVOR | COM NEW | 929033207 | 35.4 | 1.7% | 1,925,066 | Unchanged | |
| SAB Biotherapeutics IncSABS | COM NEW | 78397T202 | 31.1 | 1.5% | 7,967,207 | Unchanged | |
| Inventiva SAIVA | ADS | 46124U107 | 30.9 | 1.5% | 8,163,191 | Added+3,188,285 | |
| Aura Biosciences IncAURA | COM | 05153U107 | 30.5 | 1.4% | 4,298,248 | Added+4,068,384 | |
| Tyra Biosciences IncTYRA | COM | 90240B106 | 25.8 | 1.2% | 806,986 | Reduced−469,982 | |
| Opus Genetics IncIRD | COM | 67577R102 | 25.0 | 1.2% | 6,077,084 | Added+2,056 | |
| Anika Therapeutics IncANIK | COM | 035255108 | 21.0 | 1.0% | 1,435,130 | Unchanged | |
| Sagimet Biosciences IncSGMT | COM SER A | 786700104 | 19.3 | 0.9% | 2,500,000 | New+2,500,000 | |
| Artiva Biotherapeutics IncARTV | COM | 04317A107 | 16.8 | 0.8% | 1,736,111 | New+1,736,111 | |
| Faeth Therapeutics IncFTH | COM NEW | 81728A207 | 15.7 | 0.7% | 629,467 | Added+503,465 | |
| MBX Biosciences IncMBX | COM | 55287L101 | 11.0 | 0.5% | 200,000 | Reduced−648,590 | |
| Verrica Pharmaceuticals IncVRCA | COM SHS | 92511W207 | 5.7 | 0.3% | 923,910 | Unchanged | |
| Agios Pharmaceuticals IncAGIO | COM | 00847X104 | 3.3 | 0.2% | 90,000 | Call | Unchanged |
| Adma Biologics IncADMA | COM | 000899104 | 2.5 | 0.1% | 300,000 | Call | Unchanged |
| Cellectar Biosciences IncCLRB | COM NEW | 15117F880 | 1.3 | <0.1% | 469,998 | New+469,998 |
Sold out: 5 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| CG Oncology IncCGON | COM | 156944100 | 0.0 | 0.0% | 0 | Call | Sold out−900,000 |
| Maze Therapeutics IncMAZE | COM | 578784100 | 0.0 | 0.0% | 0 | Sold out−614,962 | |
| Mineralys Therapeutics IncMLYS | COM | 603170101 | 0.0 | 0.0% | 0 | Sold out−2,772,654 | |
| Spyre Therapeutics IncSYRE | COM NEW | 00773J202 | 0.0 | 0.0% | 0 | Sold out−878,127 | |
| Xilio Therapeutics IncXLO | COM | 98422T209 | 0.0 | 0.0% | 0 | Sold out−112,128 |
Source: SEC EDGAR, Form 13F-HR, accession 0001420506-26-001809 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.